Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY...Clinical Collaboration and Supply Agreement • May 9th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of January 13, 2022 (the “Effective Date”) by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 665 3rd St, San Francisco, CA 94107 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”). Olema and Novartis are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
CLINICAL COLLABORATION AND SUPPLY AGREEMENTClinical Collaboration and Supply Agreement • October 15th, 2021 • Immix Biopharma, Inc. • Pharmaceutical preparations • New York
This Clinical Collaboration and Supply Agreement (this “Agreement”), made as of August 20, 2021 (the “Effective Date”), is by and between IMMiX BioPharma, Inc., a corporation organized under the laws of the State of Delaware, having its place of business at 10573 West Pico Blvd., # 58, Los Angeles, CA 90064 (“Immix) and BeiGene, Switzerland GmbH, a Swiss corporation with a principal place of business at Aeschengraben 27, 21st Floor, 4051 Basel, Switzerland (“BeiGene”). BeiGene and Immix are each referred to herein as a “Party” and are collectively referred to as the “Parties”.
